← Back to headlines
New England Journal of Medicine Publishes Phase 1/2 Data on Revolution Medicines' Daraxonrasib for NSCLC
Revolution Medicines has published early clinical trial results for its experimental drug daraxonrasib (RASONQUE) targeting metastatic non-small cell lung cancer, marking a significant step in evaluating its safety and efficacy profile.
2 Sept, 21:50 — 2 Sept, 21:50
Related Stories
UNICEF Report Reveals 20 Million Children Face Annual Online Sexual Exploitation
25m ago
Genetically Modified Pig Kidney Sustains Patient for Record Nine Months
1h ago
Pentagon Temporarily Rescinds Testosterone Screening Guidance for Troops
6h ago
RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally
7h ago